551 related articles for article (PubMed ID: 21232653)
1. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
4. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues.
Klincová M; Sandecká V; Mikuláiová A; Radocha J; Maisnar V; Hájek R
Klin Onkol; 2011; 24 Suppl():S14-7. PubMed ID: 21923058
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
10. [Monoclonal gammopathy of undetermined significance].
Chaïbi P; Merlin L; Thomas C; Piette F
Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
12. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
Gámez B; Edwards CM
Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
14. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Richardson PG; Laubach J; Mitsiades CS; Schlossman RL; Ghobrial IM; Munshi NC; Anderson KC
Oncology (Williston Park); 2011 Jun; 25(7):594, 596. PubMed ID: 21888257
[No Abstract] [Full Text] [Related]
15. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L
Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
17. Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Br J Cancer; 2017 Sep; 117(6):835-839. PubMed ID: 28728165
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
Iwanaga M; Tomonaga M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
[TBL] [Abstract][Full Text] [Related]
19. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
20. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
